BCG vaccination status may predict sputum conversion in patients with pulmonary tuberculosis: A new consideration for an old vaccine?

Thorax

Volumn 65, Issue 12, 2010, Pages 1072-1076

  Jeremiah, Kidola ^a,b   PrayGod, George ^b   Faurholt Jepsen, Daniel ^c   Range, Nyagosya ^b   Andersen, Aase B ^d   Grewal, Harleen M S ^a   Friis, Henrik ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCAR; SPUTUM CULTURE;

EID: 78649635026     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.134767     Document Type: Article

References (27)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report WHO/HTM/TB/2008.393. Geneva: World Health Organization, 2008.
2. Sakula A. BCG: who were Calmette and Guerin? Thorax 1983;38:806-12.
3. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173-80.
4. Hesseling AC, Cotton MF, Fordham von Reyn C, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008;12:1376-9.
5. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-8.
6. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.
7. Singla R, Osman MM, Khan N, et al. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 2003;7:58-64. (Pubitemid 36427032)
8. Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tuberc Lung Dis 1996;77:124-9.
9. Guler M, Unsal E, Dursun B, et al. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007;61:231-5. (Pubitemid 46271284)
10. Gopi PG, Chandrasekaran V, Subramani R, et al. Association of conversion and cure with initial smear grading among new smear positive pulmonary tuberculosis patients treated with category I regimen. Indian J Med Res 2006;123:807-14. (Pubitemid 44269948)
11. Ministry of Health and Social Welfare Tanzania. Manual of the National Tuberculosis and Leprosy Programme in Tanzania. 5th edn, 2006.
12. Banu Rekha VV, Balasubramanian R, Swaminathan S, et al. Sputum conversion at the end of intensive phase of category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: an analysis of risk factors. Indian J Med Res 2007;126:452-8.
13. Telzak EE, Fazal BA, Pollard CL, et al. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997;25:666-70.
14. Matsuoka S, Uchiyama K, Shima H, et al. Relationship between CT findings of pulmonary tuberculosis and the number of acid-fast bacilli on sputum smears. Clin Imaging 2004;28:119-23. (Pubitemid 38402056)
15. Kennedy N, Ramsay A, Uiso L, et al. Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. Trans R Soc Trop Med Hyg 1996;90:162-6. (Pubitemid 26141087)
16. Fine PE, Ponnighaus JM, Maine N. The distribution and implications of BCG scars in northern Malawi. Bull WHO 1989;67:35-42. (Pubitemid 19104867)
17. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005;366:1443-51.
18. Ginsberg AM. What's new in tuberculosis vaccines? Bull WHO 2002;80:483-8.
19. Goonetilleke NP, McShane H, Hannan CM, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003;171:1602-9. (Pubitemid 36900097)
20. Roth A, Gustafson P, Nhaga A, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005;34:540-7.
21. Garly ML, Martins CL, Bale C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 2003;21:2782-90.
22. Jason J, Archibald LK, Nwanyanwu OC, et al. Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect Immun 2002;70:6188-95. (Pubitemid 35192710)
23. Bonifachich E, Chort M, Astigarraga A, et al. Protective effect of Bacillus Calmette- Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina. Vaccine 2006;24:2894-9.
24. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995;96:29-35.
25. Weir RE, Gorak-Stolinska P, Floyd S, et al. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis 2008;8:9.
26. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004;291:2086-91.
27. Barreto ML, Cunha SS, Pereira SM, et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis 2009:1171-3.